Finland· FI-REL-REL63587
Xolremdi
A mavorixafor product containing mavorixafor, registered in Finland by Norgine B.V.. The same ATC class is registered in 7 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Mavorixafor is registered in 7 of 19 countries.
Countries holding a registration under ATC L03AX24 (mavorixafor), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 5 of them publish a price we can compare per daily dose
Mavorixafor · ATC L03AX24
7 / 19 countries
- Belgiumprice
- Czechiaprice
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- United Statesprice
The record
At a glance
Fimea (Finland)- Active substance
- Mavorixafor
- Manufacturer
- Norgine B.V.
- Country
- Finland (FI)
- ATC code
- L03AX24
- ATC class
- Mavorixafor
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mavorixafor in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaXOLREMDINorgine B.V., Amsterdam
- IrelandXolremdi 100mg hard capsuleNorgine B.V.
- BelgiumXolremdi 100 mgNorgine
- NetherlandsXolremdi 100 mg harde capsuleNorgine B.V.
- PolandXolremdiX4 Pharmaceuticals (Austria) GmbH
- SwedenXolremdi 100 mg Kapsel, hårdNorgine BV
- IcelandXolremdiNorgine B.V.
- United StatesXOLREMDIX4 Pharmaceuticals, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Xolremdi
- Liechtenstein · Xolremdi
- Norway · Xolremdi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/aa1e5a92-5c28-4a8f-a00e-8b29023c1963 GET /v1/drugs/aa1e5a92-5c28-4a8f-a00e-8b29023c1963?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "kapseli, kova",
"route": "Suun kautta",
"ddd_unit": null,
"strength": "100 mg",
"atc_label": "mavoriksafori",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/26/2017/001-003",
"fimea_rel_id": "REL63587",
"authorised_at": "2026-04-27"
}See everything about mavorixafor.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.